健康志愿者皮下注射达托霉素的药代动力学与安全性:一项单盲随机交叉试验
这项单盲随机交叉I期试验在12名健康志愿者中比较了达托霉素10 mg/kg静脉与皮下给药的药代动力学和安全性,皮下给药峰浓度较低且达峰延迟,但AUC0-24生物等效;皮下给药相关不良事件较皮下安慰剂更频繁,未报告严重不良事件。
要点
- 皮下达托霉素10 mg/kg的AUC0-24与静脉给药生物等效。
- 皮下给药峰浓度较低且达峰延迟,但24小时总暴露量等效。
- 皮下给药相关不良事件较皮下安慰剂更频繁,无严重不良事件。
核心结论
- 单剂皮下注射达托霉素安全,AUC0-24与静脉途径生物等效,当无法静脉给药时皮下途径是潜在有效的替代方案。
研究设计与样本
- 两项周期、两治疗、单盲交叉I期试验(ClinicalTrials.gov NCT04434300),纳入12名无病史的健康参与者,随机顺序接受达托霉素10 mg/kg静脉和皮下给药,洗脱期至少2周,并匹配安慰剂(0.9%氯化钠)。
主要发现
- 皮下达托霉素达峰延迟(中位Tmax静脉0.5小时 vs 皮下4小时)且峰浓度低于静脉(Cmax静脉132.2±16.0 μg/mL vs 皮下57.3±8.6 μg/mL,P<0.001)。
- 皮下AUC0-24(937.3±102.5 μg·h/mL)显著低于静脉AUC0-24(1056.3±123.5 μg·h/mL,P=0.005),但判定为生物等效。
- 蒙特卡罗模拟显示,皮下8和10 mg/kg/24 h方案均使100%模拟个体达到目标AUC0-24。
- 皮下达托霉素相关不良事件较皮下安慰剂更频繁(25 vs 13,P=0.016),未报告严重不良事件。
关键数值与推荐
- 皮下达托霉素10 mg/kg与静脉给药AUC0-24生物等效。
- 皮下8和10 mg/kg/24 h方案在模拟中100%达到目标AUC0-24。
临床怎么用
- 作者认为当无法静脉给药时,皮下途径是潜在有效的替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Daptomycin stands as a key IV antibiotic in treating MRSA infections. However, patients facing challenges with difficult venous access require alternative administration routes. This study aimed to evaluate the pharmacokinetic (PK) profile and safety of subcutaneous (SC) daptomycin. PATIENTS AND METHODS: In a two-period, two-treatment, single-blind crossover Phase I trial (ClinicalTrials.gov NCT04434300), participants with no medical history received daptomycin (10 mg/kg) both IV and SC in a random order, with a minimum 2 week washout period together with matched placebo (NaCl 0.9%). Blood samples collected over 24 h facilitated PK comparison. Monte Carlo simulations assessed the PTA for various dosing regimens. Adverse events were graded according to Common Terminology Criteria for Adverse Events(CTCAE) v5.0. RESULTS: Twelve participants (aged 30.9 ± 24.4 years; 9 male,75%) were included. SC daptomycin exhibited delayed (median Tmax 0.5 h for IV versus 4 h for SC) and lower peak concentration than IV (Cmax = 132.2 ± 16.0 μg/mL for IV versus 57.3 ± 8.6 μg/mL for SC; P < 0.001). SC AUC0-24 (937.3 ± 102.5 μg·h/mL) was significantly lower (P = 0.005) than IV AUC0-24 (1056.3 ± 123.5 μg·h/mL) but was deemed bioequivalent. PTA demonstrated target AUC0-24 attainment for 100% of simulated individuals, for both 8 and 10 mg/kg/24 h SC regimens. Adverse events (AEs) related to SC daptomycin were more frequent than for SC placebo (25 versus 13, P = 0.016). No serious AEs were reported. CONCLUSIONS: Single-dose SC daptomycin infusion proved to be safe, exhibiting a bioequivalent AUC0-24 compared with the IV route. The SC route emerges as a potential and effective alternative when IV administration is not possible.
引用
- Maurille C, Baldolli A, Creveuil C, et al. Pharmacokinetics and safety of daptomycin administered subcutaneously in healthy volunteers: a single-blinded randomized crossover trial. J Antimicrob Chemother. 2024. PMID: 39271104. doi:10.1093/jac/dkae324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。